TY - JOUR
T1 - Electron Beam Intraoperative Radiotherapy (ELIOT) in Pregnant Women with Breast Cancer
T2 - From in Vivo Dosimetry to Clinical Practice
AU - Leonardi, Maria
AU - Cecconi, Agnese
AU - Luraschi, Rosa
AU - Rondi, Elena
AU - Cattani, Federica
AU - Lazzari, Roberta
AU - Morra, Anna
AU - Soto, Santos
AU - Zanagnolo, Vanna
AU - Galimberti, Viviana
AU - Gentilini, Oreste
AU - Peccatori, Fedro
AU - Jereczek-Fossa, Barbara
AU - Orecchia, Roberto
PY - 2017/12/1
Y1 - 2017/12/1
N2 - Background: The aim of this study was to confirm our preliminary results with in vivo dosimetry in non-pregnant breast cancer patients receiving electron beam intraoperative radiotherapy (ELIOT) and to report on the first treatment in a pregnant woman.Patients and Methods: Following our previous experience, 5 non-pregnant patients receiving ELIOT to the tumor bed after breast-conserving surgery (BCS) were studied with thermoluminescent dosimeters positioned in the subdiaphragmatic region, within the uterus, and in the ovarian region.In December 2011, the first pregnant breast cancer patient underwent BCS and ELIOT (21 Gy at 90% isodose) during the 15th week of gestation.Results: The mean dose to the subdiaphragmatic external region in the 5 non-pregnant patients was 5.57 mGy, while pelvic measurements were below 1 mGy.The actual dosimetry of the pregnant patient showed a mean subdiaphragmatic dose of 4.34 mGy, a mean suprapubic dose of 1.64 mGy, and mean ovarian doses of 1.48 mGy (right-sided) and 1.44 mGy (left-sided).The expected dose to the fetus was estimated as 0.84 mGy (0.004% of the prescribed dose).Conclusion: ELIOT as an anticipated boost to the breast could be considered in pregnant women in the early second trimester, postponing whole-breast irradiation after delivery.
AB - Background: The aim of this study was to confirm our preliminary results with in vivo dosimetry in non-pregnant breast cancer patients receiving electron beam intraoperative radiotherapy (ELIOT) and to report on the first treatment in a pregnant woman.Patients and Methods: Following our previous experience, 5 non-pregnant patients receiving ELIOT to the tumor bed after breast-conserving surgery (BCS) were studied with thermoluminescent dosimeters positioned in the subdiaphragmatic region, within the uterus, and in the ovarian region.In December 2011, the first pregnant breast cancer patient underwent BCS and ELIOT (21 Gy at 90% isodose) during the 15th week of gestation.Results: The mean dose to the subdiaphragmatic external region in the 5 non-pregnant patients was 5.57 mGy, while pelvic measurements were below 1 mGy.The actual dosimetry of the pregnant patient showed a mean subdiaphragmatic dose of 4.34 mGy, a mean suprapubic dose of 1.64 mGy, and mean ovarian doses of 1.48 mGy (right-sided) and 1.44 mGy (left-sided).The expected dose to the fetus was estimated as 0.84 mGy (0.004% of the prescribed dose).Conclusion: ELIOT as an anticipated boost to the breast could be considered in pregnant women in the early second trimester, postponing whole-breast irradiation after delivery.
KW - Breast cancer
KW - Pregnancy
KW - Radiation therapy
UR - http://www.scopus.com/inward/record.url?scp=85038353999&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85038353999&partnerID=8YFLogxK
U2 - 10.1159/000479862
DO - 10.1159/000479862
M3 - Article
AN - SCOPUS:85038353999
VL - 12
SP - 396
EP - 400
JO - Breast Care
JF - Breast Care
SN - 1661-3791
IS - 6
ER -